Computed tomography-based nomogram of Siewert type II/III adenocarcinoma of esophagogastric junction to predict response to docetaxel, oxaliplatin and S-1

Figure 1 Measurements of maximal diameters and gross tumor volume based on portal venous phase contrast-enhanced computed tomography in a 65-year-old male with adenocarcinoma of the esophagogastric junction. A: Maximal diameters of the tumor before three cycles neoadjuvant chemotherapy with docetaxel, oxaliplatin and S-1 (DOS); B: Maximal diameters of the tumor after three cycles DOS; C: Gross tumor volume (GTV) of the tumor before three cycles DOS; D: GTV of the tumor after three cycles DOS.

Figure 2 Nomogram was developed to predict disease control rate of adenocarcinoma of the esophagogastric junction after three cycles of neoadjuvant chemotherapy with docetaxel, oxaliplatin and S-1. DCR: Disease control rate.

Figure 3 Receiver operating characteristic curves of the nomogram. A: Area under curve with 0.838 in training cohort; B: Area under curve with 0.824 in validation cohort.

Figure 4 Calibration curve of the nomogram. A: Calibration curve in the training cohort; B: Calibration curve in the validation cohort.